MA46355A - Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide - Google Patents

Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide

Info

Publication number
MA46355A
MA46355A MA046355A MA46355A MA46355A MA 46355 A MA46355 A MA 46355A MA 046355 A MA046355 A MA 046355A MA 46355 A MA46355 A MA 46355A MA 46355 A MA46355 A MA 46355A
Authority
MA
Morocco
Prior art keywords
malignities
dimethoxyquinolin
dicarboxamide
genitourinary
cyclopropane
Prior art date
Application number
MA046355A
Other languages
English (en)
Inventor
Andrea B Apolo
Original Assignee
The Us Secretary Department Of Health And Human Services Office Of Technology Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Us Secretary Department Of Health And Human Services Office Of Technology Transfer filed Critical The Us Secretary Department Of Health And Human Services Office Of Technology Transfer
Publication of MA46355A publication Critical patent/MA46355A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA046355A 2016-09-27 2017-09-27 Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide MA46355A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662400481P 2016-09-27 2016-09-27
US201762457952P 2017-02-12 2017-02-12
US201762459340P 2017-02-15 2017-02-15
US201762552296P 2017-08-30 2017-08-30

Publications (1)

Publication Number Publication Date
MA46355A true MA46355A (fr) 2019-08-07

Family

ID=60190916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046355A MA46355A (fr) 2016-09-27 2017-09-27 Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide

Country Status (7)

Country Link
US (2) US20210275515A1 (fr)
EP (1) EP3518928A1 (fr)
JP (1) JP2019529476A (fr)
AU (1) AU2017336547A1 (fr)
CA (1) CA3038500A1 (fr)
MA (1) MA46355A (fr)
WO (1) WO2018064191A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
MY210421A (en) 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
EP3867646A1 (fr) * 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Procédés de diagnostic et de thérapie pour le cancer sarcomatoïde du rein
AU2021318134A1 (en) * 2020-07-31 2023-03-02 Exelixis, Inc. Combinations for the treatment of cancer
WO2022115464A1 (fr) * 2020-11-25 2022-06-02 Nanocopoeia, Llc Particules de cabozantinib amorphes et utilisations associées
US20220362235A1 (en) * 2021-02-19 2022-11-17 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
US20220280500A1 (en) * 2021-02-19 2022-09-08 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
WO2022177983A1 (fr) 2021-02-19 2022-08-25 Slayback Pharma Llc Compositions pharmaceutiques de cabozantinib
US20220387418A1 (en) * 2021-02-19 2022-12-08 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
EP4658271A1 (fr) 2023-01-31 2025-12-10 Handa Oncology, LLC Compositions de cabozantinib améliorées et procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
KR20180056807A (ko) 2010-07-16 2018-05-29 엑셀리시스, 인코포레이티드 C-met 조절제 약제학적 조성물
CA2826751C (fr) 2011-02-10 2021-05-18 Exelixis, Inc. Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant

Also Published As

Publication number Publication date
US20210275515A1 (en) 2021-09-09
WO2018064191A8 (fr) 2019-04-18
WO2018064191A1 (fr) 2018-04-05
US20230130243A1 (en) 2023-04-27
AU2017336547A1 (en) 2019-05-02
CA3038500A1 (fr) 2018-04-05
JP2019529476A (ja) 2019-10-17
EP3518928A1 (fr) 2019-08-07

Similar Documents

Publication Publication Date Title
MA46355A (fr) Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
EP3852608A4 (fr) Compositions et méthodes destinées à traiter le glaucome
HUE051998T2 (hu) Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére
IL257663B (en) Oral care compositions and methods of use
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
EP3471780A4 (fr) Traitement de la dmla à l'aide d'un variant d'aav2 et d'aflibercept
DK3472183T3 (da) Variant adeno-associerede virus og fremgangsmåder til anvendelse
EP3368560A4 (fr) Variants du facteur viii à cpg réduit, compositions, procédés et utilisations pour le traitement d'affections hémostatiques
IL256805B (en) Compounds -4-)-n aryl(phenyl)-2-(4-(1,1-(difluoroalkyl(phenyl)-acetamide and their use for the treatment of diseases modulated by rorgt
DK3735295T3 (da) Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3405215T3 (da) Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3320093A4 (fr) Compositions et procédés d'identification, d'évaluation, de prévention et de traitement du cancer à l'aide d'isoformes de slncr
EP3407900A4 (fr) Appareil et méthodes pour l'application topique d'oxyde nitrique
DK3262037T3 (da) Nyt quinolinderivat til anvendelse til behandling og forebyggelse af virusinfektioner
EP3706743A4 (fr) Canaux ioniques modifiés sensibles à un ligand et méthodes d'utilisation
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3416665A4 (fr) Formulation et procédé d'utilisation
EP3551612A4 (fr) Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes